Adding autologous tumor lysate-loaded dendritic cell vaccination to standard of care associated with clinical improvement in overall survival for patients with newly diagnosed and recurrent glioblastoma
1. In this phase 3 nonrandomized controlled trial, among 331 patients, patients with newly diagnosed glioblastoma (nGBM) receiving dendritic cell ...